The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
LRRK2, 2011Increased Sensitivity to the Loss of Nigrostriatal Dopamine Following Progressive MPTP Treatment in LRRK2 Mutant Small Models
Objective/Rationale:
It is known that a mutation of specific gene, called LRRK2, increases the risks of developing Parkinson’s disease in humans. The specific objective of this proposal is to... -
Target Validation, 2011Gene Delivery of MiRNAs to Reduce Alpha-synuclein: A New Therapy for PD
Objective/Rationale:
Alpha synuclein is a protein that in excessive amounts is implicated in Parkinson’s disease (PD). Alpha synuclein is also known to be the major constituent of a signature... -
MJFF Research Grant, 2011Generation of Alpha-synuclein Filament Protein and Characterization of Alpha-synuclein Rabbit Monoclonal Antibodies
Objective/Rationale:
Aggregation of alpha-synuclein plays a pivotal role in the development of Parkinson’s disease. This subproject focuses on supporting the MJFF initiative of generating monoclonal... -
MJFF Research Grant, 2011Screening & Identification of Small-molecule Pharmacophores Modulating LRRK2 Activity
Objective/Rationale:
Excessive activity of a human enzyme, named “LRRK2”, is closely associated with Parkinson’s Disease (PD). Small chemical compounds that inhibit this enzyme may be extremely... -
MJFF Research Grant, 2011Validation of Lysosomal Enzymes Assay in CSF - One-year Extension of the RRIA: CSF Lysosomal Hydrolases' Activity as Possible Marker of Parkinson's Disease
Promising Outcomes of Original Grant:
To date, there is no accepted diagnostic test based on biochemical analysis of blood or cerebrospinal fluid (CSF) for clinical diagnosis of PD. Recent studies... -
Therapeutics Development Initiative, 2011Proof of Concept of Treatment with Novel Hydroxypyridinone Iron Chelators in a Non-Clinical Model of Parkinson's Disease
Objective/Rationale:
We will test two novel, orally bioavailable, brain-penetrant iron chelators in a pre-clinical model of Parkinson’s disease (PD) for their ability to reduce labile iron-associated...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.